250.41
1.07%
-2.70
After Hours:
251.75
1.34
+0.54%
Overview
News
Price History
Option Chain
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp. stock is currently priced at $250.41, with a 24-hour trading volume of 3.09M.
It has seen a -1.07% decreased in the last 24 hours and a -1.72% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $253.1 pivot point. If it approaches the $249.6 support level, significant changes may occur.
Previous Close:
$253.11
Open:
$249.03
24h Volume:
3.09M
Market Cap:
$185.48B
Revenue:
$23.89B
Net Income/Loss:
$4.76B
P/E Ratio:
31.58
EPS:
7.93
Net Cash Flow:
$5.78B
1W Performance:
+4.60%
1M Performance:
-1.72%
6M Performance:
+27.21%
1Y Performance:
-1.55%
Danaher Corp. Stock (DHR) Company Profile
Name
Danaher Corp.
Sector
Industry
Phone
202-828-0850
Address
2200 Pennsylvania Avenue NW, Suite 800W, Washington, DC
Danaher Corp. Stock (DHR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
Dec-18-23 | Initiated | HSBC Securities | Hold |
Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
Jul-19-23 | Initiated | Raymond James | Outperform |
May-01-23 | Initiated | SVB Securities | Outperform |
Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Aug-17-22 | Resumed | Bernstein | Outperform |
Jul-20-22 | Initiated | UBS | Buy |
Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-11-22 | Initiated | Bernstein | Outperform |
Oct-15-21 | Resumed | Cowen | Outperform |
Sep-10-21 | Reiterated | BofA Securities | Buy |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-23-21 | Reiterated | Goldman | Buy |
Jul-16-21 | Initiated | The Benchmark Company | Buy |
Apr-07-21 | Resumed | Robert W. Baird | Outperform |
Mar-03-21 | Resumed | Barclays | Overweight |
Dec-02-20 | Initiated | Goldman | Buy |
Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Feb-03-20 | Reiterated | Needham | Buy |
Jan-08-20 | Initiated | Wells Fargo | Overweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Nov-15-19 | Resumed | Stifel | Hold |
Oct-28-19 | Reiterated | Needham | Buy |
Oct-14-19 | Resumed | Credit Suisse | Outperform |
Jul-19-19 | Reiterated | Needham | Buy |
Jun-11-19 | Initiated | Piper Jaffray | Neutral |
May-30-19 | Initiated | Wolfe Research | Outperform |
Apr-17-19 | Reiterated | Needham | Buy |
Feb-28-19 | Reiterated | Needham | Buy |
Feb-25-19 | Upgrade | Janney | Neutral → Buy |
Jan-03-19 | Initiated | Needham | Buy |
Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp. Stock (DHR) Latest News
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Zacks Investment Research
Tesla To $180? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
Benzinga
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
Zacks Investment Research
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
Danaher Corp. Stock (DHR) Financials Data
Danaher Corp. (DHR) Revenue 2024
DHR reported a revenue (TTM) of $23.89 billion for the quarter ending December 31, 2023, a -10.33% decline year-over-year.
Danaher Corp. (DHR) Net Income 2024
DHR net income (TTM) was $4.76 billion for the quarter ending December 31, 2023, a -33.92% decrease year-over-year.
Danaher Corp. (DHR) Cash Flow 2024
DHR recorded a free cash flow (TTM) of $5.78 billion for the quarter ending December 31, 2023, a -21.89% decrease year-over-year.
Danaher Corp. (DHR) Earnings per Share 2024
DHR earnings per share (TTM) was $6.39 for the quarter ending December 31, 2023, a -33.78% decline year-over-year.
Danaher Corp. Stock (DHR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Raskas Daniel | SVP - Corporate Development |
Feb 26 '24 |
Option Exercise |
58.48 |
23,757 |
1,389,309 |
61,859 |
Raskas Daniel | SVP - Corporate Development |
Feb 26 '24 |
Sale |
252.00 |
23,757 |
5,986,764 |
38,102 |
LOHR WALTER G | Director |
Feb 15 '24 |
Option Exercise |
52.56 |
3,289 |
172,870 |
17,418 |
LOHR WALTER G | Director |
Feb 15 '24 |
Sale |
251.15 |
3,289 |
826,032 |
14,129 |
Couchara Georgeann | SVP, Human Resources |
Feb 13 '24 |
Option Exercise |
70.71 |
2,622 |
185,414 |
6,022 |
Couchara Georgeann | SVP, Human Resources |
Feb 13 '24 |
Sale |
242.67 |
2,622 |
636,290 |
4,244 |
List Teri | Director |
Feb 06 '24 |
Option Exercise |
52.56 |
3,289 |
172,870 |
23,015 |
List Teri | Director |
Feb 06 '24 |
Sale |
248.32 |
3,289 |
816,724 |
19,726 |
Gutierrez-Ramos Jose-Carlos | SVP, Chief Science Officer |
Aug 21 '23 |
Sale |
250.54 |
590 |
147,819 |
6,939 |
Raskas Daniel | SVP - Corporate Development |
Jul 28 '23 |
Option Exercise |
56.70 |
11,213 |
635,777 |
49,501 |
About Danaher Corp.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Cap:
|
Volume (24h):